Q2 2025 Financial Highlights - Revenue grew by 6.3%, with organic revenue growth of 5.5%[9] - Adjusted Net Income increased by 17.0%[9] - Adjusted EBITDA increased by 13.9%, leading to a 170 bps increase in Adjusted EBITDA margin[9] - Free Cash Flow generated was $364 million for the last twelve months ended June 30, 2025[9] Q2 2025 Revenue Breakdown - Industrial revenue increased by 7.6% (7.0% organic), reaching $338 million[21, 22] - Consumer revenue increased by 5.6% (4.7% organic), reaching $340 million[24, 25] - Software and Advisory revenue increased by 4.3% (3.2% organic), reaching $98 million[27, 28] Q2 2025 Profitability - Industrial Adjusted EBITDA increased by $20 million, with Adjusted EBITDA margin increasing by 370 bps to 34.6%[22, 21] - Consumer Adjusted EBITDA increased by $4 million, with Adjusted EBITDA margin increasing by 20 bps to 19.1%[25, 24] - Software and Advisory Adjusted EBITDA remained flat, with Adjusted EBITDA margin decreasing by 70 bps to 15.3%[28, 27] Full-Year 2025 Outlook - The company affirms its 2025 outlook, expecting mid-single-digit constant currency organic revenue growth[34, 36] - Adjusted EBITDA margin organic improvement is expected to be approximately 24%[36] - Capital expenditures are expected to be 7% to 8% of revenue[36]

These slides contain forward-looking statements that are subject to risks and uncertainties. These statements often include words such as "believe", "anticipate", "plan", "expect", "intend", "will", "should", "could", "would", "project", "continue", "likely", and similar expressions. In particular, these slides may contain forward-looking statements about the Company's expectations for future periods with respect to its plans to improve financial results, the future of the Company's end markets, changes in ...

Financial Performance & Guidance - IAC's consolidated Adjusted EBITDA grew by 15% [8] - Full-year 2025 Adjusted EBITDA guidance is between $247 million and $285 million [8] - People Inc expects Q3 2025 Digital revenue growth of 7%-9% and total Adjusted EBITDA between $68 million and $73 million [54] - For FY 2025, People Inc expects Digital revenue growth between 7%-10% [54] People Inc (Formerly Dotdash Meredith) - Digital revenue growth accelerated to 9% [8] - Digital Adjusted EBITDA margin was 24% in Q2 2025 [32] - People Inc's Digital revenue for Q2 2025 was $260 million [32] - People Inc's Digital Adjusted EBITDA for Q2 2025 was $63 million [32] Care.com - Care.com's revenue for the last twelve months ending June 30, 2025, was $360 million [46] - Care.com's Adjusted EBITDA for the last twelve months ending June 30, 2025, was $46 million [46] - Care.com expects revenue declines of 4%-7% in Q3 [54]

Financial Performance - Sales increased by 6% year-over-year, driving an increase in gross profit[11] - Organic sales increased 5.6% year-over-year[13] - Adjusted EBITDA decreased 3.9% to $71.1 million, primarily due to increased operating expenses and transactional foreign exchange headwinds[11, 13] - Adjusted EBITDA margin was 24.7%[13] - Adjusted diluted earnings per share (EPS) decreased slightly to $2.03 due to factors impacting adjusted EBITDA[12] Segment Performance - Sealing Technologies sales increased 1.9% year-over-year[15] - Sealing Technologies adjusted EBITDA decreased 3.2% to $63.3 million, with a margin of 33.8%, a contraction of 170 bps[19] - Advanced Surface Technologies sales increased 14.5% year-over-year[21] - Advanced Surface Technologies adjusted EBITDA increased 3.7%[22] Capital Structure and Cash Flow - Upsized senior notes to $450 million (2033) and doubled revolving credit facility to $800 million (2030)[24] - Free cash flow for the six months ended June 30, 2025, was $52.8 million, up from $35.5 million in the prior year[24] 2025 Guidance - Revenue growth is projected to be 5% to 7%[26] - Adjusted EBITDA is projected to be $270 million to $280 million[26] - Adjusted diluted EPS is projected to be $7.60 to $8.10[26]

Financial Performance Highlights - Total Investment Income (TII) increased by 143% from $125 million in Q1 2025 to a record $143 million in Q2 2025[6, 11] - Net Investment Income (NII) increased from $46 million ($040 per share) in Q1 2025 to $59 million ($051 per share) in Q2 2025[6, 13] - Net assets increased from $1323 million ($1146 per share) in Q1 2025 to $1400 million ($1210 per share) in Q2 2025[6, 16] - The company issued approximately 24000 shares through the at-the-market equity program, generating net proceeds of about $03 million[6] Portfolio Composition - The fair value of the total portfolio is $3351 million[10] - Debt investments constitute 649% of the portfolio, with a fair value of $2174 million and a weighted average current yield of 125%[21, 10] - CLO investments account for 165% of the portfolio, with a fair value of $554 million[21] - Floating rate debt represents 73% of the debt holdings, while fixed rate debt accounts for 27%[27] CLO Platform - The company deployed $532 million into the CLO JV and $62 million directly into one CLO Equity position[42] - The CLO JV holds majority equity positions in three CLOs with exposure to $11 billion of underlying assets[42] - The company received approximately $118 million of distributions from the CLO JV since its inception in April 2024, resulting in an IRR of 182%[42] Distribution - The Board approved a distribution of $037 per share for the quarter ending September 30, 2025[6, 7] - This distribution equates to an annualized yield of 135% on the closing market price of $1098 on August 1, 2025, and 122% on the June 30, 2025 NAV of $1210 per share[6, 7]

Financial Performance - Revenue reached $1.69 billion, a 3% year-over-year increase[12] - Non-IFRS Gross Margin was 25.2%, flat year-over-year[12] - Non-IFRS Earnings per Share were $0.42, an 11% year-over-year increase[12] - Adjusted free cash flow margin was approximately 16% for the quarter[17] Strategic Initiatives and Investments - GlobalFoundries announced $16 billion in US investment plans supported by several companies[17] - GlobalFoundries entered into a definitive agreement with a local Chinese foundry to ensure customers will benefit from the combination of GlobalFoundries' Automotive grade process technologies with reliable domestic supply in China[29] - GlobalFoundries is expected to generate over $1 billion of adjusted free cash flow in 2025[51] Key Partnerships and Acquisitions - Continental announced the establishment of an Advanced Electronics & Semiconductor Solutions organization, a fabless semiconductor unit which will utilize GlobalFoundries as its manufacturing partner[21] - GlobalFoundries to Acquire MIPS to expand GF portfolio with cutting-edge RISC-V processor IP and software tools for real-time computing in autonomous mobility, industrial automation, data center and AI applications[25] End Market Performance - Automotive revenue increased by 36% year-over-year, reaching $368 million[39] - Smart Mobile Devices revenue was $683 million, a decrease of 10% year-over-year[37]

Financial Performance - The net leverage ratio as of Q2 2025 was 4.1x[1,2] - Net loss for the six months ended December 28, 2024, was $326.916 million, while net income for the six months ended June 28, 2025, was $29.299 million[1] - Interest expense, net, for the six months ended December 28, 2024, was $81.396 million, and for the six months ended June 28, 2025, was $67.893 million[1] - Depreciation and amortization for the six months ended December 28, 2024, was $92.250 million, and for the six months ended June 28, 2025, was $68.055 million[1] - Adjusted EBITDA for the twelve months ended June 28, 2025, was $537.822 million[1] - Debt Agreement Adjusted EBITDA for the twelve months ended June 28, 2025, was $532.968 million[1] Debt and Cash Flow - Total debt as of June 28, 2025, was $2.376724 billion[1] - Cash and cash equivalents as of June 28, 2025, were $166.131 million[1] - Net debt as of June 28, 2025, was $2.210593 billion[1] Adjustments to EBITDA - Pro forma EBITDA adjustments resulted in a decrease of $23.535 million[1] - Run rate adjustments related to store openings and closings resulted in an increase of $11.395 million[1] - Other adjustments permitted under the Debt Agreement resulted in an increase of $7.287 million[1]

Financial Performance - Revenue grew by 8% year-over-year in Q2 2025, driven by a 10% increase in the BDS (Biopharmaceutical and Diagnostic Solutions) segment, offsetting a 2% decline in the Engineering segment[12, 30] - High-Value Solutions (HVS) accounted for 42% of total revenue in Q2 2025[12] and increased 13% year-over-year to €116.8 million[30] - Gross profit margin increased by 210 bps to 28.1%[31] - Adjusted EBITDA increased to €65.1 million, with an adjusted EBITDA margin increase of 240 bps to 23.2%[31] - Net profit was €29.7 million, or €0.11 of diluted EPS[31] Segment Performance - BDS segment revenue increased by 10% to €244 million, with a gross profit margin increase of 350 bps to 31.2%[33, 34, 35] - Engineering segment revenue decreased by 2% to €36.5 million, with a gross profit margin decrease to 6.6%[36, 37] Capacity Expansion and Investments - Capital expenditure (CAPEX) in Q2 2025 was €69.1 million[40] - Net cash generated from operations in Q2 2025 was €44.9 million[40] - Free cash flow in Q2 2025 was negative €13.0 million[40] - The company announced financing agreements totaling €200 million to support capacity expansion in Latina and Fishers facilities[40] Outlook - The company maintains its FY 2025 revenue guidance of €1.160 billion - €1.190 billion, representing a year-over-year growth of 5% to 8%[42] - The company expects HVS to account for 40% to 42% of revenue in FY 2025[42] - Adjusted diluted EPS is projected to be €0.50 - €0.54 for FY 2025[42] - Adjusted EBITDA is projected to be €288.5 million - €301.8 million for FY 2025[42]

Financial Performance - Q2 2025 - Recurring revenue for Q2 2025 was $492 million, a decrease of 2.6% compared to the proforma adjusted Q2 2024[13] - Project revenue for Q2 2025 was $36 million, a decrease of 20% compared to Q2 2024's $45 million[13] - Total revenue for Q2 2025 was $528 million, a decrease of 4% compared to the proforma adjusted Q2 2024's $250 million[13] - Adjusted Gross Profit for Q2 2025 was $205 million, a decrease of 6.4% compared to the proforma adjusted Q2 2024's $219 million, with a margin of 38.8%, down 100 bps[13] - Adjusted EBITDA for Q2 2025 was $127 million, a decrease of 0.8% compared to the proforma adjusted Q2 2024's $128 million, but the margin increased by 80 bps to 24.1%[13] Revenue Growth Drivers & Outlook - The initial 2025 outlook for revenue from new wins was ~5-7%, which was updated to ~3.5-5.5%[16] - The initial 2025 outlook for revenue from volumes was ~0-1%, which was updated to ~0%[16] - The contract renewals are expected to have a negative impact of (6.5)% on revenue, consistent with the initial outlook[16] - The overall revenue impact is projected to be between (3)% and (1)%, with revenue between $2.282 billion and $2.329 billion[16,18] - The company has 95% of projected 2025 revenue under contract[18] FY25 Outlook - Adjusted EBITDA is projected to be between $620 million and $645 million, representing a growth of 4% to 9%[18] - Adjusted EPS is projected to be between $0.58 and $0.64, representing a growth of 2% to 12%[18] - Free Cash Flow is projected to be between $250 million and $285 million, representing a growth of 13% to 29%[18]

Financial Performance - Total net revenue for Q2 2025 was $800372 thousand, a decrease of 01% compared to Q2 2024's $805975 thousand[5] - Adjusted EBITDA for Q2 2025 was $155544 thousand, with an Adjusted EBITDA Margin of 194%[5] - Net income attributable to AdaptHealth Corp for Q2 2025 was $14674 thousand[5] Revenue Breakdown - Net sales revenue for Q2 2025 totaled $504715 thousand, representing 631% of total net revenue[5, 10] - Net revenue from fixed monthly equipment reimbursements for Q2 2025 was $264587 thousand, accounting for 330% of total net revenue[5, 10] - Net revenue from capitated revenue arrangements for Q2 2025 was $31070 thousand, which is 39% of total net revenue[5, 11] Segment Performance - Sleep Health generated $334689 thousand in net revenue in Q2 2025[11] - Respiratory Health contributed $170450 thousand in net revenue in Q2 2025[11] - Diabetes Health accounted for $144961 thousand in net revenue in Q2 2025[11] - Wellness at Home generated $150272 thousand in net revenue in Q2 2025[11]